Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Jessica A. Slostad"'
Publikováno v:
Cancer Medicine, Vol 11, Iss 24, Pp 4954-4965 (2022)
Abstract Background Accurate diagnostic biomarker testing is crucial to treatment decisions in breast cancer. Biomarker testing is performed on core needle biopsies (CNB) and is often repeated in the surgical specimen (SS) after resection. As differe
Externí odkaz:
https://doaj.org/article/e731e81538ff49b092098380493e0cdd
Autor:
Jessica A. Slostad, MD, Minetta C. Liu, MD, Jacob B. Allred, MS, Lori A. Erickson, MD, Kandelaria M. Rumilla, MD, Matthew S. Block, MD, PhD, Michael Keppen, MD, David King, MD, Svetomir N. Markovic, MD, PhD, Robert R. McWilliams, MD
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 5, Iss 6, Pp 1012-1020 (2021)
Objective: To evaluate the prognostic significance of detectable circulating cell-free DNA (cfDNA) BRAF V600E/K mutations in patients with advanced melanoma enrolled in a clinical trial without BRAF-targeted therapy. Patients and Methods: BRAF V600E/
Externí odkaz:
https://doaj.org/article/eba5613feb94492ca5a70349231da792
Autor:
Claudia B. Perez, Ritu Ghai, Nicole K. Yun, Ankur Naqib, Casey Frankenberger, Lydia Usha, Jessica A. Slostad
Publikováno v:
Oncologist
Next-generation sequencing (NGS) technologies have become increasingly used for managing breast cancer. In addition to the conventional use of NGS for predicting recurrence risk and identifying potential actionable mutations, NGS can also serve as a
Publikováno v:
Cancer Research. 81:PS2-34
Accurate diagnostic biomarker testing, including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her2) expression profile, is crucial to appropriate management decisions in breast cancer. Receptor sta
Publikováno v:
Mayo Clinic Proceedings. 95:e59-e64
Publikováno v:
Journal of Pain and Symptom Management. 57:e3-e5
Publikováno v:
Journal of Clinical Oncology. 39:e15037-e15037
e15037 Background: Despite advances in biomarker-directed cancer therapies to predict tumor response to treatment, precision oncology remains an imprecise science. Tumor organoid drug screens present an opportunity to test multiple potentially effect
Autor:
John M. Leitch, Rajini Katipamula, Robert R. McWilliams, Jessica A. Slostad, David M. King, Lisa A. Kottschade, Roxana S. Dronca, Svetomir N. Markovic, Kandelaria M. Rumilla, Alan H. Bryce, Lori A. Erickson, Richard W. Joseph, Jacob B. Allred
Publikováno v:
Cancer. 124:537-545
Background Despite the success of immune checkpoint and targeted therapy, many patients with melanoma ultimately require further treatment. The combination of carboplatin, paclitaxel, and bevacizumab (CPB) has demonstrated promising activity in a sin
Autor:
Jessica A. Slostad, Candace L. Haddox, Jonas Paludo, Patrick Hoversten, Kamila I. Cisak, Ayalew Tefferi
Publikováno v:
American Journal of Hematology. 93:E47-E49
Publikováno v:
BMJ Case Rep
Gestational breast cancer (GBC) is the most common form of invasive cancer in pregnancy and has unique challenges in both staging and treatment given the dual goal of appropriate cancer management and minimising the risk of fetal toxicity. A 38-year-